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ABSTRACT 
 Prostate cancer is a worldwide health concern. Pygopus2 (hPygo2) protein is 
required for growth in breast, ovarian, cervical and prostate cancer. hPygo2 expression is 
regulated by the Rb protein via the ETS factor Elf-1 in cervical and breast cancer. 
Additionally, the ETS family has confirmed roles in carcinogenesis and proliferation. The 
mechanism of hPygo2 expression has not been elucidated in prostate cancer. My 
hypothesis proposes that hPygo2 expression is regulated by Elf-1 bound to its promoter 
region. Prostate cancer cell lines were used to show protein levels of hPygo2, Elf-1 and 
ETS. ChIP assays confirmed varying binding capability of Elf-1 and ETS factors to the 
proximal promoter region between cell lines. Elf-1 knockdown experiments were 
performed, results show no change in hPygo2 protein levels but show reduction in 22Rv1 
mRNA levels. These results suggest that Elf-1 might not be exclusively involved in the 
activation of Pygopus expression in prostate cancer. 
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Chapter I - Introduction 
1.1.1 Incidence and Statistics  
 Prostate cancer is a growing health concern in many countries, especially in Western 
society. Worldwide, prostate cancer is the most diagnosed non-skin cancer in men and its 
mortality is second only to lung and bronchial cancer (Adams and Ferrington, 2014). In Canada, 
the incidence continues to rise causing it to be the most frequently diagnosed cancer amongst 
Canadian men. According to Canadian Cancer Statistics published for 2014, one in eight men is 
expected to be diagnosed with prostate cancer in their lifetime. Currently, 23 600 new prostate 
cancer cases are expected, representing 24% of all new male cancer cases (Cuzick et al., 2014; 
Canadian Cancer Society’s, 2014). In the United States for 2014, prostate cancer represents the 
second leading cancer in estimated new cancer cases and deaths in males, representing 27% 
(233,000 cases) of all new cancer cases in men according to the American Cancer Society 
(Siegel et al., 2014).  
 Improved treatments and early detection of prostate cancer have reduced the number of 
prostate cancer related deaths but there is no effective cure for advanced disease (Shen and 
Abate-Shen, 2010; Sfanos and Marzo, 2012). Locally confined disease and early diagnosis 
results in 100% survival within 5-years, however, in case of advanced disease and metastasis, the 
5-year survival is reduced to 33%  (MacVicar and Hussain, 2013).  
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1.1.2 Anatomy and histology of the prostate gland 
 The normal prostate is a gland located under the bladder around the urethra. Its main 
function is to produce secretory components for the seminal fluid. Since the prostate gland lacks 
a globular structure, it is defined as having 3 zones according to the classic work of McNeal; the 
central zone, the transition zone and the peripheral zone which harbors the majority of prostate 
carcinomas (McNeal, 1969, 1980, 1981; Timms, 2008; Shen and Abate-Shen, 2010)  Figure 1.1. 
This structure with an acinar morphology originates from the endodermal epithelial and meso-
dermal stromal cells. Normal development of the prostate starts in the Wolffian and urogenital 
sinus (McNeal, 1981).  
 
 
Figure 1. 1 A- Prostate gland location B- Zonal division of the prostate gland 
Adapted from McNeal (1981) by permission 
  
 The normal prostate epithelium has three differentiated epithelial cell types, luminal, 
basal and neuroendocrine cells Figure 1.2. Luminal cells are the predominant cells forming a 
continuous layer in the prostate epithelium producing secretory proteins. They are androgen 
receptor positive and express the markers cytokeratins 8 and 18, and CD57. The basal cells, also 
known as myoepithelial cells are located beneath the luminar epithelium and do not produce 
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secretory proteins. They present low androgen receptor levels and express p63, cytokeratins 5 
and 14, and CD44 (Abate-Shen and Shen, 2000; DeMarzo et al., 2003). The least populous 
epithelial prostate cells are the androgen independent neuroendocrine cells. While their function 
is still unclear, they express chromogranin A, serotonin and neuropeptides, and it is believed that 
they provide signals for growth of luminal cells (Sfanos and Marzo, 2012; Shen-Li et al., 2000; 
Shen and Abate-Shen, 2010). Noticeably, an increase in the presence of neuroendocrine-like 
cells is typical of small cell carcinoma, a very aggressive form of prostate cancer (Shen and 
Abate-Shen, 2010).  
 
 
Figure 1. 2 - The three differentiated cell types within the prostate epithelium 
Adapted from Abate-Shen and Shen (2000) by permission 
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1.1.3 Prostate cancer initiation and progression 
 Prostatic intraepithelial neoplasia (PIN) is widely considered a precursor of prostate 
cancer; findings suggest that its presence initiates when certain processes such as inflammation, 
oxidative stress and DNA damage affect the normal prostatic epithelium. PIN is characterized by 
an increase in luminal cells, reduction of basal cells and altered structure in the cells resulting in 
less adhesion and cytoskeleton changes (Shen and Abate-Shen, 2010; DeMarzo et al., 2003). 
Progression of PIN into adenocarcinoma is due to the activation of oncogenes, inactivation of 
tumor suppressors and re-activation of pathways involved in development. Advanced forms of 
PIN show an acinus architecture lined by luminal-like cells that seem to be malignant (DeMarzo 
et al., 2003). Histological evidence suggests that an abundant number of carcinomas have zones 
of high-grade PIN from which carcinoma glands seem to arise  (DeMarzo et al., 2003). 
 Adenocarcinoma is characterized by the complete absence of basal cells and the sustained 
proliferation of luminal-like cells. The previous thriving epithelial cells can lose their polarity 
and cell adhesion, gaining migratory properties that allow them to metastasize to other parts of 
the body, usually lymph nodes and bone (Shen and Abate-Shen, 2010). Figure 1.3 
 
Figure 1. 3 - Prostate cancer progression  
Adapted from Abate-Shen and Shen (2000) by permission 
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1.1.4 Risk factors 
 Understanding the different factors that determine the risk of developing prostate cancer 
is a very challenging and extensive task. There are, however, at least three well-known risk 
factors identified: age, race and heredity.  The following section discusses these along with other 
risk factors mentioned in the literature. 
1.1.4.1 Age 
 Age is the principal risk factor for prostate cancer. A rapid increase on the incidence of 
prostate cancer after the age of 50 is noticeable in a significant proportion of the population. In 
fact, prostate cancer incidence increases faster with age compared to other kind of cancers. 
Precursor lesions can be detected in men under the age of 40, however the majority of prostate 
cancer diagnoses occur in men after 65 years of age (Cuzick et al., 2014; Fradet et al., 2009). In 
Canada, around 100 men are diagnosed of 100 000 between 50-54 years, 500 per 100 000 men 
between 60-64 years and more than 700 per 100 000 men that are over the age of 80 (Fradet et 
al., 2009; McDavid et al., 2004).  Although there is no sole cause for this manifestation, it is 
hypothesized that among other factors, the relationship between age and prostate cancer is 
significantly due to the increase of oxidative stress during aging. Oxidative stress has been 
linked to different kinds of cancer by increasing DNA mutations or DNA damage, genome 
instability and cell proliferation (Visconti and Grieco, 2009).  
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1.1.4.2 Race and geography 
  Prostate cancer incidence shows variation between different ethnic groups and countries. 
African-American men are the most affected group having 58% greater prostate cancer incidence than 
Caucasian males, 144% greater mortality and are also more likely to be diagnosed in an advanced stage 
while Hispanic men have 14% lower incidence and 17% lower mortality compared to Caucasian males 
in the United States (Fradet et al., 2009; Cuzick et al., 2014). The lowest incidence rates of prostate 
cancer are in Asia, the lowest annual incidence registered is 1.9 per 100,000 individuals per year in the 
city of Tianjin, China. The highest incidences are in North America, more specifically the United States 
having 197 per 100,000 individuals per year. These differences are caused by a combination of genetic 
factors, external factors like environmental exposure and even differences in health care (Grönberg, 
2003). While African American ancestry seems to be a significant factor for incidence and outcome in 
individuals, there is also a geographic influence and increase of risk with individuals introduced to the 
western society lifestyle (Sfanos and Marzo, 2012). Migration studies have revealed an increase of 
prostate cancer risk after migration to North American countries by analyzing Japanese people moving 
to the USA. Their acquired risk is noticeable, however, it only represents 50% of the risk for Caucasian 
men and 25% of the risk of African-American men. These examples suggest that the differences 
between ethnic and geographical populations are real and not only an analysis influenced by lack of 
registered incidence on the health care system of different countries (Grönberg, 2003).  
1.1.4.3 Genetic factors and heredity 
 Family history and genetics play an important role in prostate cancer incidence. Men who have a 
first-degree relative with prostate cancer have a higher risk than men without that relationship. Also, 
younger men (less 65 years old) who have a first-degree relative with prostate cancer have a higher risk, 
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getting diagnosed approximately 6 years earlier than men with no family history  (Fradet et al., 2009). 
Interestingly, men whose brothers are diagnosed have a greater risk of developing prostate cancer than 
those whose fathers had the disease, suggesting a link to chromosome X (Grönberg, 2003).  More than 
two first-line relatives with the disease increases the incidence risk by 5-11 times (Bratt, 2002).   
 A portion of the family history risk is explained by mutation of known genes but only in rare 
cases. Some of these high-risk genes include BRCA1 and BRCA2 which increases 6 times the risk in 
men younger than 65, and HOXB13 increasing the risk 4 times. High risk studies have been focused 
mainly in androgen receptor, vitamin D-receptor and other genetic polymorphisms (Grönberg, 2003; 
Cuzick et al., 2014). After all these findings, family history has been considered a risk factor but the 
majority of the prostate cancers appear not to be exclusively caused by hereditary factors. While genetic 
polymorphisms have been linked to cancer, only a handful of examples are clearly established.  
1.1.4.4 External exposure and lifestyle  
 The relationship between prostate cancer and exposure to environmental factors has been 
studied extensively by epidemiological investigation. Exposure to radiation, chemicals and diet 
have been the principal studied risk factors. Ionising radiation and ultraviolet radiation have been 
both linked to prostate cancer. It is known that high exposure to cadmium correlates highly with 
incidence of prostate cancer but it is a rare case when talking about an entire population  (Cuzick 
et al., 2014). Exposure to chemicals such as pesticides might increase the risk of prostate cancer. 
As an example, methyl bromide has been linked to prostate cancer in farm workers  (Fradet et 
al., 2009).  Exposure to cigarette smoke or being a smoker is associated with a moderate increase 
of risk of mortality once diagnosed with prostate cancer. Also, aggressive cancers have been 
associated with smokers suggesting that smoking might play part in metastatic disease. Other 
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evidence suggests smoking encourages tumor growth in prostate cancer patients, but there is no 
evidence of a direct correlation between smoking and prostate cancer initiation (Cuzick et al., 
2014; Fradet et al., 2009).    
 Diet, weight and physical activity have been factors studied in relation to prostate cancer. 
A sedentary lifestyle has been linked to higher PSA concentrations in blood and while there is no 
clear link between specific diet regimes, it has been reported that there is a relationship between 
prostate cancer and dietary fat (Cuzick et al., 2014). Noticeably, obesity has been associated with 
prostate cancer with an increased risk for aggressive disease and mortality. Studies suggestthat 
prostate cancer is associated with a diet that includes high consumption of dietary fats, red meat 
and dairy (Chan et al., 1998). While these exogenous factors might be involved in the 
development of prostate cancer, there is no sufficient evidence generated from randomized trials 
to suggest any changes on related behaviors or lifestyle  (Heidenreich et al., 2014).  
 
1.1.5 General guidelines for diagnosis and treatment 
1.1.5.1 Diagnosis 
 The main tools for diagnosis of prostate cancer are: the digital rectal exam, PSA levels 
and transrectal ultrasound guided biopsies. Diagnosis is based on the combination of these 
results and histopathological results from biopsies (Smith et al., 2007).  
 Prostate specific antigen (PSA) levels have been widely used as first screening for 
prostate cancer but there is controversy about its variation, accuracy and specificity for detection. 
The main concern is that a threshold level indicating the highest risk for diagnosis has not been 
defined (Heidenreich et al., 2014, 2008) . Based solely on PSA measurement, the risk of 
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developing prostate cancer within 7-years of testing was 34% for men with PSA values of 3-6 
ng/ml, 44% for values between 6-10 ng/ml and 71% for those with values greater than 10 ng/ml 
(Aus et al., 2004; Prensner et al., 2012). Further information about PSA as a biomarker is 
described in the next sections.  
 The standard method to obtain material in order to provide histopathological analysis is 
the transrectal ultrasound guided biopsy. Usual size for biopsies is 18G core and number of 
biopsies required for detection of prostate cancer is not clearly defined (Guichard et al., 2007).  
Studies show higher detection of prostate cancer when using at least 10 biopsy cores but each 
procedure has to be adapted to the patient consideration and other values such as PSA level and 
prostate volume (Guichard et al., 2007; Heidenreich et al., 2008). Repeats of biopsies sets are 
recommended if biopsies are negative and PSA levels are high or other observations suggesting 
prostate cancer are detected (Klotz, 2005).  
1.1.5.2 Treatment 
 The condition of the patient, tumor grade and progression of the disease within the 
prostate gland and metastasis to other tissues are all factors taken into account to select a 
treatment option. Active surveillance is the common start point for tumors that are small, low-
grade and confined to the prostate tissue. Active surveillance includes regular PSA and DREs 
tests and examination of repeated biopsies during time in order to determine if the cancer has 
progressed and there is the need for therapy (Klotz, 2005).  
 Radical prostatectomy is the most used treatment with generally effective results for stage 
T1 and T2 tumors that have not spread outside the prostate gland. It consists of an operation to 
remove the prostate gland, seminal vesicles and depending on diagnosis some of the tissue 
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around it. Additionally, for men with high risk prostate cancer, a pelvic lymphadenectomy is 
performed which surgically removes groups of lymph nodes to try to prevent recurrent disease 
(Heidenreich et al., 2014). There is still controversy in how to select patients that should have a 
lymphadenectomy from others. This surgery has been correlated to survival rates of 95%, 90% 
and 79% at 5, 10 and 15 years respectively (Ward et al., 2005; Heidenreich et al., 2014).  
 Radiation therapy, generally EBRT (external beam radiation therapy), can be used to treat 
prostate cancer at any stage but it is usually selected when the health and age of the patient is a 
concern. It consists of radiation beams that are targeted to the prostate gland. In patients with 
high-risk disease, this type of treatment has been shown to improve 5-year disease survival but 
does not insure against relapse or initiation of disease in surrounding areas (Bolla et al., 2002). 
This therapy can be used in combination of other treatments, however, surgical removal of the 
prostate is not common and is very difficult after radiotherapy. To attempt to prevent relapse, 
radiation therapy with dose escalation is usually accompanied by androgen deprivation therapy 
(Pollack et al., 2000).  The second most common radiation therapy is perineal brachytherapy 
which consists of implanting radioisotope seeds directly to the tumor trying to avoid affecting 
surrounding tissues. Low-dose seed implants are used to treat low-grade cancers contained 
within the prostate gland, which release low level radiation steadily over several months. It is 
mainly used for localized cancer using iodine-125 or palladium-103 isotopes (Blank et al., 
2000). High-dose radiation is reserved for patients with high-grade tumors, the dose is 
administered through injections in the prostate, concentrating in the affected areas.  
 Hormonal therapy is widely used especially when facing aggressive, metastatic and/or 
recurrent disease usually after surgery or radiation therapy. Androgen deprivation therapy is 
performed using luteinizing hormone-releasing hormone agonists (LHRH) which provide a rapid 
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reduction in testosterone levels using different approaches: complete androgen deprivation, 
intermittent androgen deprivation, neoadjuvant hormone therapy and adjuvant hormone therapy 
(Crawford and Hou, 2009; McLeod et al., 1997). Intermitting hormone therapy consists on 
stopping androgen deprivation once PSA detection has diminished and stabilized, but resumes if 
PSA increases again. Neoadjuvant hormone therapy consists on using androgen deprivation 
before local treatment with the goal of reducing the size of the tumor and potentially aiding in 
the effectiveness of the main treatment. Lastly, adjuvant hormone therapy is used directly after 
surgery or radiation therapy to attempt the eradication of cancer cells possibly remaining. 
Initially prostate cancer tumors respond to hormonal therapies but it is later when androgen-
independent tumors emerge.  
 Chemotherapy is the treatment selected for patients with aggressively recurrent and/or 
metastatic disease that is resistant to hormonal therapies. Docetaxel is commonly the drug 
selected for treatment, which inhibits microtubule formation in mitosis and has been tested in 
combination with other therapies like radiation or surgery  (Adams and Ferrington, 2014). 
According to randomized clinical phase III trials, Docetaxel in combination with prednisone is 
the regime of choice for men with castration-resistant disease resulting in increase of survival of 
3 months, and improvement of pain and quality of life compared to Mitoxantrone, another 
common chemotherapeutic agent used as a second-line treatment for metastatic and hormone-
refractory prostate cancer (Heidenreich et al., 2008). Additionally, new agents such as 
Cabazitaxel have been generated and tested as the next generation of taxane chemotherapy 
designed to overcome resistance to Docetaxel treatment (Crawford et al., 2015).  
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1.1.6 Biomarkers 
 Biomarkers are molecules identified as indicators of a particular state in living organisms. 
They are often used in diagnosis and treatment of prostate cancer. Research findings report 
unique changes in biological markers can be used to identify or suggest the initiation, 
progression or aggressiveness of disease. Currently, prostate cancer diagnosis is frequently based 
on the prostate-specific antigen (PSA), which has provided many advantages like enhanced 
detection at early stages of disease but comprises disadvantages due to low specificity potentially 
resulting in misdiagnosis (Miller, 2012). The following section discusses current biomarkers 
used in diagnosis, prognosis and treatment of prostate cancer under 2 categories: 1) Serum 
biomarkers, referring to biomarker molecules in blood plasma identified by serum assays; and 2) 
Tissue biomarkers, referring to proteins identified and expressed in prostate cancer tissue 
specimens. 
1.1.6.1 PSA and serum biomarkers 
 Prostate specific antigen (PSA), also named kallikrein-3, is a serine protease very widely 
used and established as a serum biomarker for diagnosis and staging of prostate cancer (Partin et 
al., 1993). Low levels of PSA are detectable in the normal prostate gland but higher levels have 
been associated with disease progression. PSA has the advantage of only being produced by 
prostate tissue but challenges arise due to PSA detection sensitivity and specificity. A large 
number of studies report a correlation between PSA and cancer progression however this 
relationship is not always consistent (Crawford and Abrahamsson, 2008). Total serum PSA 
concentration (tPSA) is regularly used, and screening is often recommended by clinicians every 
year along with digital rectal examination (DRE) for men older than 50 years old. Recent 
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controversy has arisen due to evidence that suggests that tPSA values can vary a lot in patients 
with no disease and patients with benign prostate hyperplasia (BPH), potentially resulting in 
misdiagnosis (Martin et al., 2012; Prensner et al., 2012). Due to these challenges additional 
prostate serum biomarkers have been studied.  
 Kallikrien-4 (KLK-4), found in serum and tissue, is an androgen-dependent serine 
protease that has been studied as a potential biomarker. Findings have shown correlation 
between elevated levels of KLK-4 in serum and prostate cancer progression, and have suggested 
that KLK-4 increases proliferation and motility of cancer cells (Martin et al., 2012). Seiz et al., 
in 2010, reported that KLK-4 is expressed in healthy prostate and it is upregulated in early-stage 
disease but not late-stage prostate cancer. The roles of KLK-4 have not been completely 
elucidated but could present an effective way to diagnose and stage patients in conjunction with 
PSA (Harada et al., 2003).  
 Additional serum markers such as early prostate cancer antigen (EPCA-2) and prostate 
cancer gene 3 (PCA3) have been shown to be elevated in serum from prostate cancer patients but 
not present in healthy patients. Unfortunately, their specificity to prostate cancer and effective 
use as diagnostic and prognostic biomarkers needs further evaluation (Martin et al., 2012; 
Velonas et al., 2013).  
1.1.6.2 Tissue biomarkers 
 Androgen receptor (AR) is a nuclear receptor that is activated by androgens such as 
testosterone or dihydrotestosterone (Balk and Knudsen, 2008). Once bound to these hormones it 
is translocated into the nucleus where it acts as a DNA-binding transcription factor that can 
regulate normal gene expression in the prostate gland, but it also is involved in the initiation and 
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progression of prostate cancer (Heinlein, 2004). Androgen depletion therapies have been 
common in prostate cancer treatment for over 40 years resulting in an initial disease regression 
but unfortunately for aggressive disease, later progressing to an androgen independent stage 
(Debes and Tindall, 2004; Feldman and Feldman, 2001).  
 The progression from primary prostate cancer into metastatic and castration-resistant 
disease has been associated with overexpression of androgen receptor (Linja et al., 2001). 
Because AR is often upregulated in prostate cancer and therefore triggering its transcriptional 
activation of genes involved in growth, encouraging cancer progression even in absence of 
androgens; it has been considered a promising biomarker not only as a therapeutic target but also 
as a predictor of metastatic, aggressive and androgen-independent disease. 
 α-methyl-co-racemase (AMACR) is a biomarker often used in clinical diagnosis as high 
levels of the protein are associated with prostate cancer. AMACR is used primarily for 
immunohistochemistry of biopsy tissues for the detection of prostate carcinoma (DeMarzo et al., 
2003). It is used in conjunction with other biomarkers to confirm diagnosis of prostate cancer 
along with absence of basal cells. Unfortunately, AMACR is also detectable in high-grade 
prostatic intraepithelial neoplasia (PIN) and occasionally on benign glands, which challenges the 
diagnosis of low to medium grade prostate carcinoma (Esfahani et al., 2015; Qu et al., 2014; 
Martin et al., 2012).   
 Urokinase-type plasminogen activator (uPA), a serine protease, interacts with its receptor 
called uPAR, bound to the cell membrane. Their interaction has been implicated in the 
proliferation and metastasis of different cancers mainly due to its ability to activate conversion of 
plasminogen to plasmin and activate different signalling events degrading matrix proteins 
(Sheng, 2001). In prostate cancer uPA and uPAR levels are elevated compared to normal 
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prostate tissues. Both activator and receptor are used as diagnostic markers due to their unique 
expression pattern during prostate cancer and efforts are still being made for them to be used as 
therapeutic targets (Li and Cozzi, 2007; Dong et al., 2008; Sheng, 2001).   
 Steroid receptor coactivator-3 (Src-3), is a tyrosine kinase that has been identified as 
being recruited to the PSA promoter and able to interact with androgen. Findings have shown 
that this interaction correlates with tumorigenesis in breast, ovary and prostate cancer (Zhou et 
al., 2005). High expression of Src-3 in serum correlates with cell proliferation and hormone-
independence since patients that have higher expression of Src-3 are more likely to relapse 
(Zhou et al., 2005; Fizazi, 2007). Src-3 has been identified to be a potential indicator of 
metastasis and progression, inhibitors of Src-3 are being currently evaluated to assess their effect 
in controlling cancer progression (Martin et al., 2012).  
 Loss of E-cadherin expression, a protein that mediates calcium-dependent cell-cell 
adhesion and their bond to the extracellular matrix, has been related to invasion and metastatic 
ability of prostate cancer cells (Mao et al., 2010). Lower levels of active E-cadherin have been 
found in metastatic prostate cancer cell lines and promotes the release of the cells from their 
extracellular matrix and tissue (Kuefer et al., 2005). These findings suggest that this protein 
could potentially be used as an epithelial to mesenchymal transition biomarker (Zeisberg and 
Neilson, 2009). 
 Enhancer of Zeste homolog 2 (EZH2), is a protein associated with cancer metastasis in 
variety of cancers such as breast, renal and prostate cancer  (Varambally et al., 2002) . EZH2 has 
been correlated with low levels of E-cadherin expression found in tumors with poor prognosis. 
EZH2 expression is significantly higher in prostate cancer cells compared to ones with BPH or 
PIN  (Dhanasekaran et al., 2001; Martin et al., 2012). In tumors, EZH2 expression is higher in 
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disease with a Gleason score of more than 7. EZH2 has been identified as a potential therapeutic 
target mainly due to its properties as a regulator of tumor metastasis at different stages 
(Varambally et al., 2002; Shen and Abate-Shen, 2010; DeMarzo et al., 2003).  
 Prostate stem cell antigen (PSCA) is a glycoprotein present in a large proportion of 
prostate cancers  (DeMarzo et al., 2003). Although it is also found in healthy prostate tissue, 
higher levels of PSCA correlate to later cancer stage, Gleason score and androgen independence. 
PSCA was expressed in 94% of primary tumors and 100% of metastatic samples according to 
Gu et al., 2000 studies. For these reason, PSCA is considered a highly potential therapeutic 
marker in addition to being a diagnostic tool.  
 Engrailed-2 (EN2) is a member of the HOX gene family involved in embryonic 
development and shown to be re-activated in cancer progression. High levels of EN2 has been 
identified in PC-3, DU145 and LNCaP cell lines and elevated expression is correlated in tumor 
samples of genetically high risk men (Morgan et al., 2011). It is a potential diagnostic tool 
because it can be detected in urine and according to Killick et al., 2013, had a sensitivity of 
66.7% and specificity of 89.3% to detect cancer using an ELISA based detection system. It has 
the potential advantage of being used non-invasively for early detection.  
 Genomic analysis is also widely used for studying biomarkers in the use of prostate 
cancer and trying to detect individuals who are more at risk. BRCA1/2 have the most potential 
for use as markers since there is an association of BRCA2 mutations with aggressive disease and 
poor survival  (Velonas et al., 2013). Another example is prostate cancer antigen 3 (PCA3), 
which is expressed in only prostate and is currently used mainly due to its detection in urine and 
prostatic fluid. PCA3 is overexpressed in 95% of prostate cancer patients compared to those with 
healthy or BPH prostate glands  (Velonas et al., 2013; Martin et al., 2012).  
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 To date, the most frequent and detectable gene fusion in prostate cancer is 
TMPRSS2:ERG (Tomlins et al., 2005). TMPRSS2 is an androgen related serine protease that is 
secreted by prostate epithelial cells and is fused with ERG protein, a member of the ETS family, 
which will be discussed in the next sections. This fusion has a high predictive value but no 
diagnostic tests are available at the moment (Hessels et al., 2007 ). Findings claim that the 
detection of this fusion along with the regular serum PSA testing would improve the effective-
ness of diagnosis or prognosis but the value of TMPRSS:ERG detection is yet to be determined, 
mainly due to lack of correlation with Gleason scores and its presence in good prognosis patients  
(Demichelis et al., 2007; Martin et al., 2012).  
 Novel biomarkers present an opportunity to resolve the challenge of diagnosis, staging 
and treating prostate cancer. While many potential candidates have emerged there is a deficiency 
of strong well-sustained biomarkers for diagnosis and treatment able to exclusively detect cancer 
initiation, progression and/or metastasis.  
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1.1.7 Pygopus 
 Novel biomarkers present an opportunity to cover the necessity for effective molecular 
targets in their use in diagnosis, prediction and potential therapies. Our laboratory has 
concentrated its efforts on a novel biomarker called hPygo2 (Lake and Kao, 2003; Andrews et 
al., 2007, 2008, 2009; Kennedy et al., 2010; Popadiuk et al., 2006; Tzenov et al., 2013; Andrews 
et al., 2013). Pygopus2 is one of the two isoforms of the Pygopus proteins originally discovered 
as a nuclear factor of canonical Wnt/β-catenin transcription complex of the Wnt signaling 
pathway in Drosophila (Kramps et al., 2002; Belenkaya et al., 2002). Soon after, Pygopus 
homologous proteins were identified with roles in organogenesis first in Xenopus and also in 
mammals  (Lake and Kao, 2003; Li et al., 2004).  
 As reviewed by Polakis, 2012, members of the Wnt signaling pathway are involved in 
countless processes in development, growth and differentiation, which make their abnormal 
activation and mutations play a critical role in cancer progression. Without exception, Pygopus is 
highly expressed in different malignancies such as breast, ovarian, glioblastomas and gliomas, 
cervical cancer, prostate and hepatic cancer  (Andrews et al., 2007; Popadiuk et al., 2006; 
Tzenov et al., 2013; Wang et al., 2010; Chen et al., 2011; Yang et al., 2013; Zhang et al., 2015). 
Findings in development and cancer research have shown that pygopus has Wnt-independent 
roles mainly due to its function as a chromatin modifier and recent discovered roles in ribosome 
biogenesis (Andrews et al., 2009; Chen et al., 2010; Andrews et al., 2013). The following 
section discusses Pygopus2 function and its potential as a biomarker in prostate cancer. 
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1.1.7.1 Pygopus in the Wnt signaling pathway 
 Association of the Wnt/ β-catenin signaling pathway with cancer has been widely 
studied, mainly due to its requirement on growth and differentiation events  (Clevers, 2002). 
Mutations of components of this pathway have been linked to a variety of human cancers like 
colorectal, breast, ovarian and cervical cancer (Andrews et al., 2007). Activation of the canonical 
Wnt pathway causes an accumulation of β-catenin in the cytoplasm that is then translocated to 
the nucleus to act as a co-activator of TCF/LEF transcription factors binding to DNA and 
therefore initiating gene transcription (Thompson et al., 2002; Polakis, 2012). 
 In the absence of Wnt stimulation, β-catenin is phosphorylated by a destruction complex 
that includes axin, glycogen synthase 3β (GSK3β), casein kinase 1α (CK1α) and the 
Adenomatous polyposis coli (APC) tumor suppressor. Degradation depletes nuclear β-catenin 
and therefore, inhibition of gene transcription since TCF/LEF transcription factors are inactive 
due to their binding to transcriptional corepressors such as Groucho Figure 1.4.  
 Pathway activation is initiated by the binding of a Wnt ligand to the Frizzled family 
receptor, which disrupts the destruction complex, resulting in cytoplasmic β-catenin 
accumulation and nuclear translocation. Together with several proteins, β-catenin binds and 
activates the TCF/LEF transcription factor, inducing gene transcription. Proteins forming the 
activation complex of TCF/LEF with β-catenin include B-cell CLL/lymphoma 9 protein (BCL9), 
CREB-binding protein (CBP) and Pygopus (Pygo) Figure 1.5 (Thompson et al., 2002; Kramps 
et al., 2002; Lake and Kao, 2003).  
 Negative and positive acting components of the Wnt signaling pathway are affected in 
cancer cells. In cancer, a number of negative suppressing components are found to be mutated 
while positive components are activated  (Thompson et al., 2002). One factor commonly 
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identified in the disruption of the Wnt pathway is APC which is the most frequently mutated 
gene in human cancers. APC causes adenomatous polyposis which generated polyps in the large 
intestine at an early age which turn into colorectal cancer. This loss of function is required for 
cancer progression and it disrupts the ability to regulate β-catenin stability  (Polakis, 2012).    
 
Figure 1. 4–Inactive Wnt Pathway. A-Destruction complex in the cytoplasm and repression of gene 
expression in the nucleus. Axin, glycogen synthase 3β (GSK3β), casein kinase 1α (CK1α) and the 
Adenomatous polyposis coli (APC) tumor suppressor conform the destruction complex in absence of 
Wnt stimulation. B- Degradation of β-catenin in the cytoplasm by the proteasome, TCF/LEF 
transcription factors are inactive due to their binding to transcriptional corepressors such as 
Groucho. 
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Figure 1. 5- Active Wnt Pathway. A- Wnt ligand binding to FZD (Frizzled) and LRP (Lipoprotein 
receptor) receptors, disrupting destruction complex. B- β-catenin accumulation and translocation to 
the nucleus where Pygopus among other factors form a complex to activate target gene transcription. 
 
 Pygopus proteins contain an evolutionary conserved PHD domain that controls chromatin 
access for transcription complexes and binding (Thompson et al., 2002; Kramps et al., 2002; 
Belenkaya et al., 2002). Additionally, Pygopus proteins also contain an N-terminal homology 
domain (NHD), which is required to bind LEF/TCF and start Wnt-independent transcription 
(Jessen et al., 2008). While much of the initial studies focused on the role of Pygopus in 
canonical Wnt-mediated gene transcription, Wnt-independent roles of Pygopus2 were revealed 
when knockdown experiments eliminated both β-catenin dependent and independent genes 
required for forebrain and retina development in Xenopus (Lake and Kao, 2003). Furthermore, 
Pygopus Wnt-independent functions have been studied in development and in a variety of cancer 
malignancies (Popadiuk et al., 2006; Thompson et al., 2002; Song et al., 2007).  
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1.1.7.2 Pygopus relationship to cancer 
 High expression levels of hPygo2 have been reported in different malignancies such as 
breast, ovarian, glioblastomas and gliomas, cervical cancer, prostate and hepatic cancer  
(Andrews et al., 2007; Popadiuk et al., 2006; Tzenov et al., 2013; Wang et al., 2010; Chen et al., 
2011; Yang et al., 2013; Zhang et al., 2015). As reported by Popadiuk et al., 2006, six different 
epithelial ovarian cancer cell lines, including Wnt-active and Wnt-inactive cells, overexpressed 
nuclear hPygo2 compared to normal ovarian epithelial cells. Additionally, 82% of patient tumors 
also overexpressed hPygo2 compared to benign disease, and when hPygo2 knockdowns were 
performed, both Wnt-active and Wnt-inactive cancer cell lines demonstrated growth arrest. 
These results suggest that even in the absence of Wnt signaling, hPygo2 is expressed and 
required for growth and therefore important for its potential as a diagnostic biomarker and 
therapeutic agent (Popadiuk et al., 2006).  
 In breast cancer, hPygo2 levels were elevated in malignant tumors and knockdown 
experiments resulted in halted growth of MCF-7 and MDA-MB-468 cell lines. Along with 
anchorage-independent assays, these results demonstrate a requirement for hPygo2 in breast 
cancer growth (Andrews et al., 2007). According to Wang et al., 2010, tumor grade correlated 
with the overexpression of hPygo2 in glioma tissue samples. Additionally, when knocking down 
hPygo2 expression in the glioblastoma cell line U251, results showed reduction in proliferation 
and arrest of the cells suggesting that hPygo2 is required for growth (Wang et al., 2010). The 
requirement for Pygopus2 in cervical cancer was also assessed showing high hPygo2 levels in 
higher-grade lesions than in normal epithelial cells using a cervical cancer progression 
microarray. Pygopus2 protein and mRNA levels were significantly greater in HPV-positive 
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cervical cancer cells compared to uninfected cells confirming a relationship between E7 protein, 
retinoblastoma protein, Elf-1 factor and expression of hPygo2 (Tzenov et al., 2013).  
 In prostate cancer, Dr. Kao’s lab found elevated expression of hPygo2 in androgen-
dependent and independent cell lines compared to normal epithelial control and as expected, 
hPygo2 knockdown resulted in reduction in growth and proliferation in cell lines. Furthermore, 
hPygo2 was expressed in most radical prostatectomy tissue samples assessed by 
immunohistochemistry (unpublished). Recent work has reported the role of hPygo2 in ribosome 
biogenesis during cancer cell growth, showing hPygo2 binding to known ribosome production 
proteins like treacle and UBF (upstream binding factor) in nucleoli of cancer cell lines and 
potentially recruiting histone acetyl transferases (HAT)s to rDNA promoter to increase 
transcription for cell growth and proliferation (Andrews et al., 2013). Pygopus2 knockdown 
experiments resulted in growth arrest in both p53 positive and negative cell lines, down-
regulation in rRNA production, and triggering of ribosomal stress pathway resulting in cell arrest 
at G1 phase in p53-positive cells (Andrews et al., 2013).   
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1.1.8 Pygopus relationship to the ETS factor family 
 The ETS transcription factor family of proteins, activate or repress the expression of 
genes involved in myriad biological processes. ETS factors’ function in cellular proliferation, 
differentiation, transformation and apoptosis have increased the interest to research their 
molecular mechanisms and how they control transcription (Seth and Watson, 2005). Their 
capability to be involved in these processes could give insight into controlling and understanding 
cancer development.   
 In breast, ovarian and cervical cancer hPygo2 was found to be activated by Elf-1 (E74-
like-1) factor, an ETS family transcription factor regulated by the retinoblastoma protein (Rb) 
(Andrews et al., 2008; Tzenov et al., 2013).  The following section discusses the ETS 
transcription factor family, their roles in cancer and their potential activation mechanism of 
hPygo2 in prostate cancer. 
1.1.8.1 ETS family  
 The ETS family in humans consist of 27 highly evolutionarily conserved transcription 
factors that have critical roles in biological processes such as cell proliferation, differentiation, 
transformation and apoptosis Table 1.1 (Hsu et al., 2004). The discovery of this large family of 
conserved genes started with the identification of the v-ets oncogene (E26) of avian leukemia 
virus (Oikawa and Yamada, 2003; Hsu et al., 2004). ETS proteins share a conserved winged 
helix-turn-helix DNA binding domain called the ETS domain, which binds to DNA sequences 
containing GGAA/T exclusively. Additionally, some of the ETS proteins also have a pointed 
domain (PNT) used in protein-protein interactions Figure 1.6. More than 200 ETS target genes 
have been identified and the number of verified genes that are positively or negatively regulated 
 25 
 
by ETS transcription binding sites are constantly increasing (Sementchenko and Watson, 2000). 
ETS transcriptional regulation is dependent on interaction with other factors and it is known that 
translational modifications can affect the activity of different ETS proteins involved in 
compartmentalization, transactivation or stability (Seth and Watson, 2005). 
 
 
Figure 1. 4 – ETS-1 prototype member of ETS family, PNT and ETS Domains 
Crystalized structures of domains obtained from MMDB public accessions (Mackereth et al., 2004; 
Newman et al., 2015)     
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Table 1. 1 - ETS subfamilies and members 
Adapted from Gutierrez-Hartmann et al., 2007 
 
1.1.8.2 ETS factors in carcinogenesis 
 ETS transcription factors have very important targets that include oncogenes, tumor 
suppressor genes, apoptosis and differentiation related genes, and not surprisingly, invasion and 
metastasis related genes. Consequently, aberrant expression of ETS factors can create a chain of 
changes that contributes to cancer initiation, progression and metastasis  (Seth and Watson, 
2005). The presence of the ETS sequence in the oncogenic virus E26 was the first time a 
connection was confirmed between ETS factors and cancer (Sementchenko and Watson, 2000; 
Seth and Watson, 2005). Different ETS factors are modified (deleted or mutated) and have 
abnormal expression patterns in leukemia, prostate cancer, breast cancer and sarcomas (Oikawa, 
2004; Oikawa and Yamada, 2003). The following table summarizes examples of ETS family 
target genes involved in different processes of carcinogenesis Table 1.2. 
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Table 1. 2 - ETS family targets involved in carcinogenesis 
Based on Hsu et al., 2004; Seth and Watson, 2005; Oikawa and Yamada, 2003; Sementchenko and 
Watson, 2000 
 
1.1.8.3 ETS factors in prostate cancer 
 Chromosomal rearrangements remain the principal studies involving ETS family genes in 
prostate cancer. Successful analyses of chromosomal rearrangements have elucidated important 
genes with aberrant expression able to have oncogenic properties in leukemia, lymphomas and 
sarcomas (Tomlins et al., 2008; Shaikhibrahim and Wernert, 2012). These rearrangements occur 
when promoter or enhancer elements of one gene are juxtaposed to an oncogene causing an 
aberrant expression of the protein. In the case of ETS factors in prostate cancer, these 
rearrangements fuse two genes, resulting in a fusion protein that has a new or aberrant activity 
involved in cancer progression (Martin et al., 2012; Turner, 2010) . As previously discussed, the 
main gene fusion involving ETS family in prostate cancer occurs with the prostate-specific 
serine protease TMPRSS2 gene and most commonly the ERG gene. Other family members have 
also been identified being fused to TMPRSS2 including ETV-1, ETV-4 and ETV-5 
(Shaikhibrahim and Wernert, 2012). Since TMPRSS2 is an androgen-regulated protein, these 
rearrangements increase the expression of ETS members in response to androgens. As reviewed 
by Shaikhibrahim and Wernert, 2012; several studies suggest that ETS rearrangements are the 
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key for prostate cancer initiation but there is controversy indicating that they might aid cancer 
progression once initiation has already started. Overexpression of TMPRSS2-ERG in primary 
prostate cancer induced invasion but not proliferation while fusions with ETV-1 and ETV-4 
increased invasion, growth and proliferation in prostate cancer cell lines (Turner, 2010; Oikawa 
and Yamada, 2003). 
 Several ETS genes have been studied for their properties in cancer progression and 
invasion. For example, the genes encoding ETS-1, FLI1, ERG, ELF-1 and PDEF are highly 
expressed in tumors while ETV-4 and ELK-1 are not expressed in prostate cancer tissues. 
Expression analysis of all the ETS family members in prostate cancer have been reported by 
quantitative RT-PCR using tissue from normal prostate glands and moderately differentiated 
tumor glands from radical prostatectomies, these analyses have reported that only 3 family 
members, EHF, ELK-4 and ETS-2 exhibit significant differences in expression between normal 
and tumor glands. In cell lines, qRT-PCR was performed to detect levels of expression of ETS 
family members in the androgen dependent cells VCaP and LNCaP, and the androgen 
independent cells PC3 and DU-145. Each cell line has a unique expression pattern of ETS family 
member without a clear correlation to their androgen status or aggressiveness (Shaikhibrahim et 
al., 2011; Shaikhibrahim and Wernert, 2012). Investigation of the roles, expression and 
importance of ETS family members in prostate cancer is currently at an early stage since 
attention brought initially by the TMPRSS2-ERG fusion.  
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1.1.8.4 Pygopus and the Elf-1 factor 
 As mentioned in previous sections, high expression levels of hPygo2 have been reported 
in different cancer cell lines and tissues in breast, ovarian, glioblastomas and gliomas, cervical 
cancer, prostate and hepatic cancer (Andrews et al., 2007; Popadiuk et al., 2006; Tzenov et al., 
2013; Wang et al., 2010; Chen et al., 2011; Yang et al., 2013; Zhang et al., 2015). In prostate 
cancer, findings show a similar trend with elevated expression of hPygo2 in androgen-dependent 
and independent cell lines compared to normal epithelial control and reduction in growth and 
proliferation of cell lines when hPygo2 is eliminated by knockdown (Kao et al., unpublished).  
 The mechanism of Pygopus2 regulation has not yet been elucidated in prostate cancer, 
however previous evidence in cervical and breast cancer indicated that hPygo2 gene expression 
is regulated by the Retinoblastoma protein (Rb) via Elf-1, an ETS factor involved in 
tumorigenesis in breast, ovarian and cervical carcinomas (Andrews et al., 2008; Tzenov et al., 
2013). The retinoblastoma tumor suppressor mechanism regulates Elf-1 in a similar matter to 
E2F. When Rb protein is active, its pocket region interacts with the N-terminal LXCXE motif of 
Elf-1 factor when it is bound to the promoter blocking its transactivation activity but when Rb is 
phosphorylated by Cyclin D1-cdk4 complexes, the change in conformation de-represses Elf-1 at 
the promoter region being able to activate target gene expression, in this case of hPygo2 Figure 
1.7 (Wang et al., 1993; Adnane et al., 1995; Alt et al., 2000; Andrews et al., 2008). The previous 
mechanism is important due the fact that loss and aberrant expression of Rb is a key factor in 
prostate cancer progression which would allow Elf-1 to initiate hPygo2 transcription and 
therefore promote growth (Sharma et al., 2010; Kao et al., unpublished).  
 
 30 
 
 
Figure 1. 5 - Pygopus expression is regulated by Elf-1 via Rb. A- Rb binds to Elf-1 blocking its 
activation of gene expression at the promoter region. B- CyclinD1 and CDK4 phosphorylate Rb, de-
repressing Elf-1 at the promoter and starting gene transcription. 
 
1.1.8.5 HPV infection and its relationship to pygopus and prostate cancer 
 Human papilloma virus (HPV) is a transmitted infection that has been associated with 
development of several epithelial cancers including cervical, anal, penile and vaginal cancers 
(Aghakhani et al., 2011; Dillner et al., 1998). In particular, HPV16 and HPV18 are known to 
cause around 70% of cervical cancer cases (Carozzi et al., 2003). Since HPV-16 and 18 are 
transmitted sexually it has been hypothesized that HPV may also be a risk factor for prostate 
cancer. A large number of studies have tried to correlate this infection to the initiation and 
progression of prostate cancer, however, most of the results are subject to large controversy due 
to lack of clear correlations (Aghakhani et al., 2011; Hisada et al., 2000; Effert et al., 1992; Al-
Maghrabi, 2007). 
 In cervical cancer, Tzenov et al., 2013 confirmed a mechanistic relationship between E7 
protein, one of the primary oncoproteins of high risk HPV, and Elf-1 transactivation regulating 
hPygo2 protein. The findings reported that hPygo2 overexpression in cervical cancer is due to 
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E7 protein inducing the degradation of the Rb, consequently de-repressing Elf-1 and initiating 
hPygo2 gene transcription Figure 1.8 (Tzenov et al., 2013). While the presence of HPV 16 and 
18 has been assessed before in different prostate cancer cell lines and tissues, the presence of E7 
protein acting upon Rb protein and initiating Elf-1 activation of target genes has not been 
elucidated in prostate cancer (Tu et al., 1994; Moyret‐ Lalle and Marcais, 1995; Dillner et al., 
1998; Adami et al., 2003; Noda et al., 1998).  
 
 
Figure 1. 6 - E7 induces degradation of Rb, de-repressing Elf-1 and activating hPygo2 gene 
transcription in cervical cancer.  
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1.1.9 Rationale  
 The mechanisms regulating hPygo2 gene activation are unknown in prostate cancer. 
Previous findings have suggested hPygo2 has an important role in prostate cancer and is required 
for cancer cell growth and proliferation (Andrews et al., 2007; Popadiuk et al., 2006; Tzenov et 
al., 2013; Wang et al., 2010; Chen et al., 2011; Yang et al., 2013; Zhang et al., 2015). In breast 
and cervical carcinomas, hPygo2 regulation by the ETS factor Elf-1 depends on degradation of 
Rb protein and since loss and aberrant expression of Rb is a key factor in prostate cancer 
progression it could potentially have a similar mechanism (Shen and Abate-Shen, 2010; 
Andrews et al., 2007; Tzenov et al., 2013) . Moreover, numerous findings have reported 
increased expression of several ETS factors and their potential roles in cancer progression (Seth 
and Watson, 2005).  
This thesis will address the mechanism of expression of hPygo2 in prostate cancer. It will 
evaluate the hypothesis: hPygo2 expression is regulated via Elf-1 ETS factor bound to its 
promoter region. 
1.1.10 Objectives 
 Assess the presence of HPV 16 and HPV 18 E7 proteins in prostate cancer cell lines and 
possible role on hPygo2 regulation. 
 Determine the levels of hPygo2, Elf-1 and additional ETS factors at a protein level in 
different prostate cancer cell lines. 
 Assess the binding capability of Elf-1 and additional ETS factors to hPygo2 proximal 
promoter region. 
 Evaluate the effect on hPygo2 expression by performing a knockdown of the Elf-1 factor in 
prostate cancer cell lines.  
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Chapter II – Materials and Methods 
2.1 Cell culture 
 The following five characterized prostate cancer cell lines, 22Rv1 (Sramkoski et al., 
1999), LNCaP (Horoszewicz et al., 1983), DU 145 (Stone et al., 1978), MDA PCa 2b (Navone 
et al., 1997) and PC-3 (Kaighn et al., 1979) were obtained from the American Tissue Culture 
Collection (ATCC; CRL-2505, CRL-1740, HTB-81, CRL-2422 and CRL-1435 respectively, 
Virginia, USA). 22Rv1 and LNCaP were cultured in Roswell Park Memorial Institute 1640 
Medium (RPMI 1640; Gibco Life Technologies; California, USA) while DU 145, MDA PCa 2b 
and PC-3 were cultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco Life 
Technologies; California, USA), 10% Fetal Bovine Serum (FBS; Gibco Life Technologies 
California, USA) was added to complement both media. Passage ratio was 1:3 and cells were 
passaged approximately every 3 days. Normal prostate epithelial cell line, PrEC (Sobel et al., 
2005) was obtained from Lonza (Lonza Group Ltd; CC-2555; Basel, Switzerland) and grown in 
their specific Prostate Epithelial Cell Growth Medium (Clonetics PrEGM; Lonza Group Ltd; 
Basel, Switzerland). Source, androgen status and PSA presence has been previously confirmed 
for all of the prostate cell lines Table 2.1.  
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Table 2. 1 - Prostate cell lines, their source, androgen sensitivity, androgen receptor and PSA status 
 
  
 Additionally, normal human endocervical primary cell line HEN and the following 
immortalized cancer cell lines in vitro by HPV 16 and 18, HEN 16 and HEC 18 (Donations by 
Dr. Pater’s Laboratory, Memorial University) (Yang et al., 1996; Tsutsumi et al., 1992) were 
maintained in Dulbecco's Modified Eagle Medium (DMEM; Gibco Life Technologies; 
California, USA). For HEN primary cells, 50 µg/ml bovine pituitary extract (BPE; Gibco Life 
Technologies; California, USA) and 5 ng/ml epidermal growth factor (EGF; Gibco Life 
Techonologies; California, USA) were added to complement the media. For HEN 16 and HEC 
18 cell lines, 10% Fetal Bovine Serum (FBS; Gibco Life Technologies; California, USA) was 
added to DMEM media. 
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2.2 RNA extraction and cDNA generation 
 Total RNA extraction was performed using the RNeasy Mini Kit (Qiagen; C#74104; 
Hilden, Germany) on 6-well multiple well plates (Corning Inc.; New York, USA) with 
approximately 1 x 106 cells per well at the time of extraction following manufacturer’s 
instructions. Synthesis of complementary DNA was implemented by following Invitrogen’s M-
MLV Reverse Transcriptase protocol with a total final volume of 20 µl per sample. Procedure 
started with incubation of 1 µg of extracted RNA, 0.2 µg random primers (oligo-dT; Invitrogen; 
California, USA), 0.5 mM dNTP and dH2O at 65 °C for 5 min followed by incubation of First 
Strand Buffer (FS Buffer, Invitrogen; California, USA), 10mM DTT and 10 units of 
Recombinant Ribonuclease Inhibitor (RNase Out, Invitrogen; California, USA) for 2 min at 
37°C. Lastly, 50 units of Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT, 
Invitrogen; California, USA) were added to samples and incubated at 25°C for 10 min, 37°C for 
50 min and 70°C for 15 min, using the GeneAmp PCR System 9700 (Applied Biosystems; 
California, USA) (Tzenov et al., 2013; Chang et al., 2010).  
 
2.3 Reverse transcription PCR (RT-PCR) analysis and Real time Quantitative PCR  
 Each PCR reaction was prepared by adding 1X PCR buffer-MgCl, 5 mM MgCl, 200 µM 
dNTP, 1 unit of Platinum Taq Polymerase (Invitrogen; California, USA), dH2O, 2 µl of each 
primer (Final concentration of 0.8 M) and 1 µg of the respective cDNA for a final volume of 50 
µl. Primer sequences are listed in Table 2.2 (Dharmacon; Colorado, USA).  Each PCR reaction 
with their specific primers was subjected to the following conditions as described in Lake and 
Kao, 2003: 94°C for 4 min followed by 35 cycles at 94°C for 30 sec, 60°C for 30 sec and 72°C 
for 30 sec finalizing with 7 min at 72°C, using a GeneAmp PCR System 9700 (Applied 
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Biosystems; California, USA). The PCR products were run in 2% agarose gel electrophoresis, 
stained with SYBR Safe Gel DNA Stain (SYBR Safe; Invitrogen; California, USA) and 
analyzed with Gel Doc EZ Imager (Biorad; California, USA). RT-PCR analysis was performed 
to detect presence of HPV 16 and 18 E7 protein in cervical cell lines and prostate cancer cell 
lines. 
 Real time quantitative PCR (RT-qPCR) was performed to measure levels of Elf-1 and 
hPygo2 in Elf-1 siRNA treated samples and non-targeting siRNA control samples using the Step 
One Plus Real time PCR system and software (Applied Biosystems; California, USA). cDNA 
samples were amplified using RT2 SYBR green master mix (Qiagen; Hilden, Germany) and 
1.25 µM of the primers listed in Table 2.3 using the standard 2-hour long run in the system 
(Andrews et al., 2008). Data was analyzed using the relative quantitative comparative threshold 
cycle (ΔΔCt) method using β-actin as control and one-way repeated measures ANOVA followed 
by an Fisher’s LSD statistical analysis for multiple comparisons (p<0.05 for significance) using 
Prism 6 software (Graphpad Prism, California, USA).  
Table 2. 2 - Primer sequences used in RT-PCR analyses 
 
 
Forward Primer (5'-3') Reverse Primer (5'-3') Reference
E7  FOR 
HPV16
TCC AGC TGG ACA AGC 
AGA AC
CAC ACC CGA AGC GTA 
GAG TC
(Tzenov et al. , 2013)
E7  FOR 
HPV18
AAC ATT TAC CAG CCC 
GAC GA
TCG TCT GCT GAG CTT 
TCT AC
(Tzenov et al. , 2013)
ELF-1 
CCA GTC ACC CAT GTG 
TCC GTC AC
CAC AGA TAT ATT TGG 
CGT AGT GGC TG
(Tzenov et al. , 2013)
β-ACTIN 
ATC TGG CAC CAC ACC 
TTC TAC AAT GAG CTG CG
ATG GCT GGG GTG TTG 
AAG GTC TC
Invitrogen Control 
(Andrews et al. , 
2008)
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Table 2. 3 - Primer sequences used in Real Time qPCR 
 
 
2.4 Protein extraction, SDS Page and immunoblotting 
 Protein was extracted from 80-85% confluent plates in radioimmunoprecipitation assay 
buffer (RIPA buffer, .01% SDS; 1.1% Triton X-100; 1.2 mM EDTA; 16.7 mM Tris-HCl pH 8.1; 
167mM NaCl) adding 1 µM PMSF and protease inhibitors (Thermo Fisher Scientific; 
Massachusetts, USA). Samples were incubated at 4°C for 30 min, homogenized by resuspension, 
centrifuged for 10 min at 4°C, and then collected.  
 Total protein quantities were normalized by Bio-Rad protein assay (Bio-Rad Laboratories 
Inc.; California, USA) with a standard curve generated using BSA as reference. Equivalent 
protein sample of 25µg were loaded onto 10% SDS-denaturing polyacrylamide gels or 4-20% 
Mini-PROTEAN gels (Mini-PROTEAN TGX; Bio-Rad Laboratories Inc.; California, USA) for 
knockdown experiments, and subsequently transferred to polyvinylidene difluoride membrane 
(PVDF Trans-Blot® Turbo™ membrane, Bio-Rad Laboratories Inc.; California, USA) using the 
Western Blot Trans-Blot® Turbo™ Transfer System (Bio-Rad Laboratories Inc.; California, 
USA). After transfer, membranes were blocked for 1 hour with 5% Skim Milk in Tris-Buffered 
Saline and Tween 20 solution (TBST), later to be incubated overnight at 4°C with their specific 
Forward Primer (5'-3') Reverse Primer (5'-3') Reference
ELF-1
CCA GTC ACC CAT GTG TCC 
GTC AC
CAC AGA TAT ATT TGG CGT AGT 
GGC TG
(Tzenov et al. , 2013)
HPYGO2
GTC CCC CAC TCC ATG GCC 
GCC TCG
GCT TCT TTT CTG GAC TCT TC (Andrews et al., 2008)
β-ACTIN 
ATC TGG CAC CAC ACC TTC 
TAC AAT GAG CTG CG
ATG GCT GGG GTG TTG AAG GTC 
TC
Invitrogen Control                     
(Andrews et al., 2008)
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antibodies and appropriate dilution Table 2.4. TBST washes were performed before incubating 
for 1 hour at room temperature with the respective secondary antibody, Donkey anti-rabbit IgG-
HRP or goat anti-mouse IgG-HRP (Abcam; Cambridge, UK), and then washed again. 
Immunodetection was achieved using Clarity™ ECL Western Blotting Substrate (Bio-Rad 
Laboratories Inc.; California, USA) and CL-Xposure™ Film (Thermo Fisher Scientific; 
California, USA). Densitometry analysis was performed using scanned film at an 8-bit 
conversion using peak gel analysis tool of ImageJ software. Peak area and percentage of each 
band was divided by their respective loading control band in order to calculate a particular 
relative density. (Popadiuk et al., 2006)  
Table 2. 4 - Antibodies, source and dilution used in protein immunoblots. 
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2.5 Chromatin immunoprecipitation 
 22Rv1, DU-145 and PC-3 cells were seeded in 100 mm dishes (Corning Inc.; New York, 
USA) and grown to 80-85% confluence. Cross-links between protein and DNA were achieved 
by incubating for 10 min with 0.75% formaldehyde, followed by 125mM glycine to quench the 
process. After, cells were washed with PBS, harvested and resuspended in lysis buffer (50 mM 
Tris-HCl (pH   8.0);   150   mM   NaCl;   1   mM   EDTA;   1%   Triton X-100; 0.1% Na-
deoxycholate; dH2O) containing protease inhibitors. Cross-linked cells were sonicated to 
produce 500 bp genomic DNA fragments using sonicator at 15% power repeating 7 times the 
following: 10 seconds pulse and 20 seconds pause; for a total of 1:10 min treatment.  
 Collected chromatin was pre-cleared with preblocked protein A beads (50% slurry, 
Millipore; Massachusetts, USA) at 4° C for 1 hour. Supernatants were incubated overnight at 4 
°C with 2 µg of their respective antibodies followed by addition of 20 µl protein A agarose beads 
and incubated for 1 hour Table 2.5. The pellets extracted were then washed for 5 min twice with 
1 ml of each of the following buffers, low salt immune complex wash buffer, high salt immune 
complex wash buffer, LiCl immune complex wash buffer, and TE buffer Table 2.6.  
 Protein-DNA complexes were eluted in 180 µl of elution buffer (1.0% SDS; 100 mM 
NaHCO3; dH2O) for 30 min and cross-links were reversed overnight at 65°C. DNA was purified 
using QIAquick PCR purification kit (Qiagen; Hilden, Germany) and eluted in 30 µl dH2O. All 
samples were amplified by real-time quantitative PCR using RT2 SYBR green master mix 
(Qiagen; Hilden, Germany) with hPygo2 proximal promoter region primers (hPygo2 -102u: 5'-
CAG GCG TAG CGT CTC GTC CGG TC-3', hPygo2 +74d: 5'-CCG AGC TGC AGC AAC 
CAC AAA GTG-3'). Analysis was performed using the relative quantitative comparative 
threshold cycle (ΔΔCt) method against input chromatin levels and one way ANOVA analysis for 
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multiple comparisons against IgG followed by an uncorrected Fisher’s LSD statistical analysis 
(p<0.05 for significance) using Prism 6 software (Appendix A2) (Graphpad Prism, California, 
USA) (Matthews et al., 2006; Andrews et al., 2008; Tzenov et al., 2013).  
Table 2. 5 - Antibodies used for chromatin immunoprecipitation assay 
  
Table 2. 6 - Chromatin Immunoprecipitation buffers and formulations 
 
2.6 Antisense Knockdowns 
 Small interfering RNA’s (SiRNA) were used to perform knockdown experiments for 
ELF-1 (ELF-1 A, Santa Cruz Biotechnology and ELF-1 B designed by Andrews et al., 2008, 
target Sequence: 5’ GAAAGAGAA-CACTGAGAAA, GE Dharmacon Healthcare Inc.; 
Colorado, USA) proteins, using siGENOME Non-Targeting siRNA Pool as a control 
(Dharmacon Healthcare Inc.; Colorado, USA). 22Rv1 and PC-3 cells were seeded in 6-well 
plates, seeding 1x105 cells per well, 24 hours before transfection.  Transfection was achieved 
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using Lipofectamine® RNAiMAX (Invitrogen; California, USA) using different concentration 
of duplexes (5nM, 10nM and 20nM) following manufacturer’s instructions and collecting cells 
after 24 hours of transfection for RNA and 48 hours for protein extraction. Western blots were 
performed to confirm the protein knockdowns and changes to hPygo2, pRb and Rb proteins. 
RNA samples were used to generate cDNA as previously described and analyzed by qRT-PCR.  
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Chapter III – Results 
3.1 Human papilloma virus E7 protein was not detectable in prostate cancer cell lines 
 The presence of E7 protein mRNA expressed by HPV16 and 18 in prostate cancer cell 
lines was assessed by RT-PCR using a normal endocervical primary cell line HEN as negative 
control, cancer cell lines harboring HPV 16 and 18, HEN 16 and HEC 18 as positive controls 
and the following prostate cancer cell lines: 22Rv1, PC-3 and DU-145. The presence of E7 
mRNA was then assessed using E7 primers for HPV16 and E7 primers for HPV18 along with β-
actin primers. In cervical cancer, E7 protein induces the degradation of the retinoblastoma tumor 
suppressor protein (Rb) releasing and allowing the transactivation of Elf-1 protein for hPygo2 
transcription (Tzenov et al., 2013). The presence of E7 protein in prostate cancer cell lines could 
suggest a similar mechanism in the requirement of hPygo2 for growth in prostate cancer. Results 
indicate that E7 HPV16 or E7 HPV18 appears to not be expressed in prostate cancer cell lines 
compared to the respective cancer endocervical cell lines suggesting that HPV infection is not 
contributing to the proposed mechanism Figure 3.1. 
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Figure 3. 1 - RT-PCR for the detection of E7 protein in prostate cancer cell lines 
RT-PCR was performed on the normal endocervical cell line HEN, endocervical cancer cell lines HEN 
16 and HEC 18 and prostate cancer cell lines 22Rv1, PC-3 and DU-145. β-actin was used as a loading 
control. Presence of E7 protein was only detectable in HEN 16 and HEC 18 for their respective primers. 
No amplification of E7 protein in prostate cancer cell lines was detectable. 
 
3.2 Differential expression of Elf-1, hPygo2 and additional ETS factors in different prostate 
cancer cell lines  
 Previous findings in breast, ovarian and cervical cancer cell lines have supported the 
mechanistic relationship between Rb, which regulates the activation of hPygo2 gene expression 
via Elf-1 activity (Andrews et al., 2009, 2008; Tzenov et al., 2013). On that premise, the 
presence and protein levels of androgen receptor, phosphorylated Rb (pRb) (inactive), hPygo2 
and, ETS factors Elf-1, Erg-1, Ets-1 and Elk-1 were assessed by immunoblot. Total Erk antibody 
was used as a loading control. Cell lines used were the normal prostate epithelial cell line PrEC, 
androgen receptor positive prostate cancer cell lines: 22Rv1, LNCaP and MDA PCa 2b, and 
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androgen receptor negative prostate cancer cell lines: DU-145 and PC-3. Androgen receptor 
status was concordant with the known status (Table 2.1) for each cell line.  
hPygo2 protein levels varied between prostate cancer cell lines but show differences from 
the normal PrEC cell line, lowest expression in the prostate cancer cell lines is shown in LNCaP 
and MDA PCa 2b. pRb protein levels correlated with hPygo2 and Elf-1 expression only in 
22Rv1 and PC-3 cell lines, while in the rest of the cell lines it was present at lower levels. Elf-1 
antibody detected different transcript variants in the prostate cancer cell lines, there is evidence 
of five different Elf-1 variants with protein activity (Okada et al., 2011; Gerloff et al., 2011; 
Yang et al., 2013). Presence of Rb levels were detected in all of the cell lines except for very low 
on DU-145, known to have a mutated Rb protein status (Ikediobi et al., 2006).  Interestingly, this 
last cell line has a high expression of hPygo2 protein levels. For the remaining ETS factors, Erg-
1 was expressed in all of the cell lines while Elk-1 was highly expressed in all of the cell lines 
including normal epithelium. Interestingly, Ets-1, the prototype member of the ETS family, was 
expressed highly in 22Rv1 and DU-145, cell lines in which hPygo2 levels were also higher. 
These protein levels confirm the presence of hPygo2 in different prostate cancer cell lines 
regardless of their androgen status and the status of Elf-1 and additional ETS factors. Figure 3.2. 
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Figure 3. 2 - Protein expression levels of hPygo2, Elf-1 and ETS factors 
Protein expression levels of hPygo2, pRb, AR, Elf-1, Erg-1, Ets-1, Elk-1 and Erk-1 as loading control 
were detected by immunoblot. Androgen receptor status is concordant with the known status for each 
cell line. hPygo2 expression is present at different levels in all of the prostate cancer cell lines and not 
on normal prostate epithelium cell line PrEC. Phosphorylation of the retinoblastoma protein is present 
at different levels in all of the prostate cancer cell lines but not on PrEC. Rb expression is present on 
all the cell lines except for DU-145 with a very low expression, concordant to its Rb mutated status. 
Erg-1 showed low protein levels in all of the cell lines while Elk-1 showed high expression in all of the 
cell lines. Ets-1 shows high expression in 22Rv1 and DU-145, cell lines that also show a high expression 
of hPygo2 levels. 
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3.3 Elf-1 and Ets-1 factors bind to the proximal promoter region of hPygo2 gene in 22Rv1 
and PC-3 prostate cancer cell lines 
 Chromatin immunoprecipitation assays were performed in 22Rv1, Du-145 and PC-3 cell 
lines in order to assess the binding capability of ETS factors to the proximal region of hPygo2 
promoter. The following cell lines were chosen because 22Rv1 shows high protein expression of 
hPygo2 and ETS factors, DU-145 shows high expression of hPygo2 but mutated Rb (which 
might give an insight of a different mechanism) and PC-3 has high protein expression of hPygo2. 
The ETS factors tested were Elf-1, Erg-1, Ets-1 and Elk-1. IgG was used as a negative control to 
compare against occupancy of ETS factors at the proximal promoter region (-102u to +74d). 
Immunoprecipitation, purification, real time q-PCR and analysis by relative quantitative 
comparative threshold cycle (∆∆CT) was performed.  Percentage of input values were 
normalized to IgG and statistical analysis was performed using a repeated measures ANOVA 
and Fisher’s LSD statistical analysis for multiple comparisons to obtain significance against IgG 
binding capacity to the specific region (p<0.05). In 22Rv1 cells, higher levels of binding of Elf-1 
and Ets-1 to the proximal promoter region of hPygo2 are significantly higher compared to IgG 
occupancy. In PC-3 cells, Elf-1 and Ets-1 also show higher levels of occupancy at the proximal 
promoter region but again only for Elf-1 this association is significant. In DU-145 cells, high 
levels of binding for all the ETS factors are seen but only Ets-1 and Elk-1 appear to be 
significant compared to IgG. As stated previously, the binding capability of Elf-1 could suggest 
activity at proximal regions of hPygo2 promoter and therefore possible induction of pygopus 
gene expression Figure 3.3.  
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Figure 3. 3 - Detection of ETS factors binding to the proximal promoter region of hPygo2 by 
chromatin immunoprecipitation 
Chromatin Immunoprecipitations amplifying for the proximal promoter region from -102u to +74d of 
hPygo2 were performed in 22Rv1, PC-3 and DU-145 cell lines in order to assess the binding capability 
of Elf-1, Ets-1, Elk-1 and Erg-1 factors against IgG. Analysis by relative quantitative comparative 
threshold cycle (∆∆CT) was performed, results were normalized and compared to the binding 
capability of IgG using comparative measures ANOVA and Fisher’s LSD statistical test (p<0.05). IgG 
normalization takes into account control variance and data input correlates each data set to their 
specific IgG mean.  
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3.4 Elf-1 knockdown reduces mRNA levels but not protein levels of hPygo2 protein  
Elf-1 silencing experiments were performed in order to assess its effect on hPygo2 
protein levels. Knockdown of Elf-1 was achieved using 2 different Elf-1 siRNA duplexes (Elf-1 
siRNA A and B) in different concentrations and a non-targeting siRNA duplex used as control 
using the 22Rv1 cell line Figure 3.4 – A. Elf-1 knockdown was performed using the lowest 
functional concentration of 5nM of the siRNA-A duplex. Elf-1 expression, change in hPygo2 
expression, and pRb were assessed by immunoblot where protein was collected at 24 hours, 48 
hours and 72 hours after transfection. Using siRNA-A, there was no noticeable detectable 
change in hPygo2 protein expression after 24 hour and 48 hours after transfection. However, at 
72 hours the non-targeting siRNA could possibly have an off target effect on pRb resulting in 
unexpected high expression of Elf-1 and hPygo2. Interestingly, at 72 hours using Elf-1 siRNA, 
hPygo2 expression is lower compared to the 72 hour non-targeting control Figure 3.4 – B & C. 
 Relative Elf-1 and hPygo2 mRNA expression in the 22Rv1 cell line for the Elf-1 siRNA-
A and non-targeting siRNA treated samples were analyzed using real time qPCR. Results show 
reduction in levels of Elf-1 in knockdown samples compared to the samples treated with a non-
targeting siRNA. Pygopus mRNA levels are significantly lower in Elf-1 siRNA-A treated 
samples (p<0.05) Figure 3.5. 
 Subsequently and due to possible non-targeting siRNA effects on the previous cell line, 
another Elf -1 knockdown was performed using the same two siRNA Elf-1 duplexes in PC-3 cell 
line. Results show Elf-1 silencing was successful but there is no significant change in hPygo2 
protein expression Figure 3.6 – A & B. These findings suggest that, unlike breast and cervical 
cancer, Elf-1 is not exclusively involved in the activation of hPygo2 expression in prostate 
cancer and the analysis of other transcription factors or mechanisms should be evaluated.  
 49 
 
 
 
Figure 3. 4 - Effect of silencing Elf-1 in hPygo2 protein expression using 22Rv1 cell line 
A- Elf-1 knockdown in a 22Rv1 cell line was performed using two different siRNA duplexes against a 
non-targeting siRNA duplex in different concentrations (5nM, 10nM, 20nM and 40nM) and protein 
levels were analyzed by immunoblot. Even a 5nM concentration shows considerably lower Elf-1 
protein expression in both cases. B- Elf-1 knockdown was performed using 5nM concentration of the 
first Elf-1 siRNA duplex, protein was collected at 24, 48 and 72 hours. Levels of hPygo2 protein 
expression were not reduced by Elf-1 silencing. C- Densitometry showing Levels of Elf-1 and hPygo2. 
Elf-1 expression is lower on Elf-1 siRNA A treated samples. However, there is only an evident change 
on 72 hour hPygo2 expression of siRNA treated against non-targeting control possibly due to an off 
target effect of the non-targeting control siRNA. No significant change was obtained by comparative 
measures ANOVA and Fisher’s LSD statistical test (p<0.05). 
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Figure 3. 5 - Pygopus mRNA expression in 22Rv1 cell line treated with Elf-1 siRNA A 
RT-qPCR analysis shows a reduction in Elf-1 in Elf-1 siRNA A treated samples compared to non-
targeting samples, significant reduction of hPygo2 in knockdown samples is shown. Ct values were 
normalized to -actin as control. Significance was obtained by comparative measures ANOVA and 
Fisher’s LSD statistical test (p<0.05). 
 
Figure 3. 6 - Effect of silencing Elf-1 in pygopus protein expression using PC-3 cell line 
A - Elf-1 knockdown in PC-3 cell line was performed using two different siRNA duplexes against a 
non-targeting siRNA duplex at 5nM and 10nM concentrations, protein levels were analyzed by 
immunoblot. Both concentrations shows considerably lower Elf-1 protein expression yet no change on 
hPygo2 protein expression is noticeable. B – Densitometry showing Elf-1 and hPygo2 levels. Results 
show significant reduction of Elf-1 using both SiRNAs. However, no significant change in hPygo2 was 
detected against the respective non-targeting control. Significance was obtained by comparative 
measures ANOVA and Fisher’s LSD statistical test (p<0.05). 
 51 
 
Chapter IV – Discussion 
4.1 The relationship between HPV and prostate cancer was not detectable 
 Current literature on the role of HPV infection in prostate carcinoma is controversial. The 
first involvement of HPV infection in carcinoma was identified in cervical cancer where HPV E6 
and E7 protein target Rb for degradation, releasing E2F transcription factor and activating the 
aberrant expression of growth and proliferation genes (zur Hausen, 1977; Moody and Laimins, 
2010). HPV infection in prostate carcinoma is of importance in relation to hPygo2 expression 
because it could explain its requirement for cell growth and proliferation. In cervical cancer, the 
presence of HPV infection generates E7 protein, which induces the degradation of Rb protein, 
and in a similar matter to E2F, Elf-1 is de-repressed initiating hPygo2 gene transcription (Tzenov 
et al., 2013). Numerous studies have examined the role of HPV infection in prostate 
carcinogenesis with inconsistent and contradictory results  (Pascale et al., 2013; Lin et al., 2011; 
Moody and Laimins, 2010; Martinez-Fierro et al., 2010; Rosenblatt et al., 2003). I performed 
RT-PCR in order to assess the presence of E7 protein in prostate cancer cell lines and therefore 
the possibility of having a similar mechanism to that of cervical cancer. Results showed that 
HPV 16 and HPV18 E7 protein is expressed in their respective endocervical cancer cell lines but 
is not expressed in prostate cancer cell lines. This result suggests that there is no relationship 
between HPV infection and expression of hPygo2 in prostate cancer cell lines. Additional 
experiments with HPV 16 and 18 infected prostate cancer cell lines and tumors could be 
performed in order to analyze interaction of E7 protein with Rb and the expression levels of Elf-
1 and hPygo2 proteins.  
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4.2 Differential expression of ETS factors in prostate cancer cell lines expressing pygopus 
protein 
 ETS proteins play an important role in the regulation of expression of genes involved in 
cellular proliferation, differentiation, transformation and apoptosis (Sementchenko and Watson, 
2000). The relationship between hPygo2 expression and the ETS factor family relies in its 
mechanism of regulation. In breast and cervical cancer, hPygo2 was found to be activated by 
Elf-1 (E74-like-1), an ETS family transcription factor regulated by Rb (Andrews et al., 2008; 
Tzenov et al., 2013). As an initial step to assess the possibility of a similar mechanism in 
prostate cancer, protein levels of Rb, pRb, Elf-1, hPygo2, Erg-1, Ets-1 and Elk-1 were analyzed 
by immunoblot.  Regardless of its androgen receptor status, all of the prostate cancer cell lines 
showed expression of Elf-1 and hPygo2 proteins. As expected, no expression of these two 
proteins was detected in the normal prostate epithelial cell line PrEC. Interestingly, hPygo2 
expression only appeared to correlate with high expression of Elf-1 in 22Rv1 and PC-3 cell lines. 
When additional ETS factors were tested, Erg-1 protein was expressed at  lower levels than other 
ETS factors, high levels of Ets-1 were present in 22Rv1 cells and Elk-1 was expressed in all of 
the cell lines but at a lower level in the normal PrEC. Unique expression of ETS family members 
between different prostate cancer cell lines have been reported before by Shaikhibrahim and 
Lindstrot (2011). Their results were similar to mine, reporting that Elf-1 (including variants) has 
higher levels in PC-3 cell, Elk-1 was higher in LNCaP cells, and Erg and Ets-1 were higher in in 
DU-145 and PC-3 cells (Shaikhibrahim and Lindstrot, 2011). The evident differences between 
ETS factor expression levels in different prostate cancer cell lines could be explained by the 
different tissue origins and metastatic properties of the cell lines making it a plausible reason of 
why hPygo2 expression varied as well.   
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4.3 Presence of ETS factors binding to the proximal pygopus promoter region in prostate 
cancer cell lines  
 Chromatin immunoprecipitation (ChIP) was performed in 22Rv1, Du-145 and PC-3 cell 
lines to assess the binding capability of Elf-1 and additional ETS factors to the proximal region 
of hPygo2 promoter. Results confirmed high and statistically significant occupancy of Elf-1 at 
the proximal promoter region in 22Rv1 and PC-3 cell lines. Moreover, Ets-1 had high occupancy 
at this region in all of the cell lines but it was only significant in 22Rv1 and DU-145. The 
presence of Elf-1 at the hPygo2 proximal promoter region was concordant with results in breast, 
ovarian and cervical cancer (Andrews et al., 2008; Tzenov et al., 2013).  
 Interestingly, Elf-1 may not be the only factor present at the proximal promoter region. 
Genome-wide analyses using a human T cell line have reported overlapping functions and 
redundant occupancy of different ETS factors at consensus gene regions, and while some of the 
ETS factors are present at specific binding sites, these sites are further away and distinct from 
transcription start sites (Hollenhorst et al., 2007). The possibility of redundant occupancy of ETS 
factors in this region is likely due to their conserved domain and preference for consensus 
binding sites. This phenomenon, however, has never been studied in prostate carcinoma cell 
lines. While most of the ETS proteins bind DNA as monomers, cooperation among different 
ETS factors and other transcriptional factors have been demonstrated where protein-protein 
interactions help regulate DNA binding, localization and transcriptional regulation of target 
genes (Kodandapani and Pio, 1996; Li et al., 2000).  
Reports show that blocking Ets-1 activity with an inverse plasmid upregulates other ETS 
family members such as Elf-1, Elf-2, Elk-1, Etv-5 and Spi-1 but there is no evidence of direct 
interaction between the factors (Shaikhibrahim and Lindstrot, 2011; Shaikhibrahim and Wernert, 
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2012). These findings raise the possibility of protein interactions within the ETS factor family 
including Elf-1 which could suggesta different mechanism of hPygo2 expression in prostate 
cancer. 
4.4 Elf-1 knockdown reduces mRNA levels but not protein levels of hPygo2 protein 
 Elf-1 knockdowns were performed in 22Rv1 and PC-3 cell lines in order to assess Elf-1 
ability to regulate hPygo2, in both cases there was no evident change in protein levels of hPygo2 
expression. However, hPygo2 mRNA levels were significantly reduced in 22Rv1. These results 
indicate that unlike breast and cervical cancer, Elf-1 is not exclusively involved in the activation 
of hPygo2 expression in prostate cancer and a redundant mechanism is likely in place to ensure 
activity of this important protein for growth. These experiments reject the hypothesis of Elf-1 
exclusively regulating hPygo2 activation. The possibility of different ETS factors being involved 
in the expression mechanism of hPygo2 needs to be evaluated. Since Ets-1 and Elf-1 show 
binding to the same proximal promoter region, it is possible that expression is being regulated by 
both or their interaction. Unfortunately, Ets-1 siRNA knockdown in prostate cancer has not been 
reported and my preliminary knockdown experiments were unsuccessful (Appendix A5). The use 
of an inverse plasmid to block Ets-1 expression as shown by Shaikhibrahim and Lindstrot (2011) 
would be very useful to confirm Elf-1 upregulation in different prostate cancer cell lines and 
observe its effect on hPygo2 expression. 
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4.5 Conclusions 
 Pygopus expression is regulated by the Rb protein via the ETS factor Elf-1 in cervical 
and breast cancer (Andrews et al., 2008; Tzenov et al., 2013). The ETS family has roles in 
regulating target genes involved in proliferation, transformation and apoptosis. Previous 
evidence in cervical cancer cell lines report that HPV 16 and HPV18 E7 protein degrades Rb, 
de-repressing Elf-1 and initiating hPygo2 expression (Tzenov et al., 2013) . To assess the 
possibility for a similar mechanism in prostate cancer, RT-PCR was performed for the detection 
of E7 protein in HPV infected endocervical cancer cell lines and prostate cancer cell lines. The 
presence of E7 was not detectable in the prostate cancer cell lines indicating that HPV infection 
is not a requirement for prostate cancer progression. 
 Variation in protein levels of ETS factors were identified between cell lines. However, 
Elf-1 and hPygo2 levels were higher in prostate cancer cells compared to the normal prostate 
PrEC cell line. To evaluate the binding capability of Elf-1 and ETS factors to the proximal 
promoter region of hPygo2, chromatin immunoprecipitation assays were performed resulting in 
high occupancy of Elf-1 in 22Rv1 and PC-3 cell lines. In 22Rv1, PC-3 and DU-145, Ets-1, 
another ETS factor, also showed high occupancy at the region suggesting Elf-1 might not 
exclusively regulate hPygo2. 
 To evaluate this, Elf-1 knockdowns were performed in 22Rv1 and PC-3 cell lines in 
order to assess the ability for Elf-1 to regulate hPygo2; in both cases there was no change in 
hPygo2 protein levels. However, hPygo2 mRNA levels were significantly reduced in 22Rv1 
cells. These results suggest that unlike breast and cervical cancer, Elf-1 might not be exclusively 
involved in the activation of pygopus expression in prostate cancer. 
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4.6 Future directions  
 The possibility of HPV E7 protein involvement in hPygo2 expression mechanism could 
be tested with known HPV 16 and 18 infected prostate cancer cell lines and tumor tissues to 
consequently analyze the expression levels of E7 protein, Rb, Elf-1, hPygo2 and additional ETS 
factors.  Immunoprecipitations could be performed in order to confirm possible interactions 
between ETS family members, particularly Elf-1 and Ets-1. Overexpression vectors and 
blocking vectors of Ets-1 could be designed and transfected into different prostate cancer cell 
lines in order to evaluate the effect on Elf-1 and hPygo2 expression levels. 
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Appendices 
A1- ChIP Ct Values 
Table A 1 - Ct values for 3 repetitions of chromatin immunoprecipitation assays for 22Rv1, DU-145 
and PC-3 cell lines 
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A2- ChIP Statistical Analysis - Data Entry 
22Rv1  
    Normalized to IgG =1 
  % of Input  
Ct Values 
 Each ETS factor value divided by their IgG value 
(Specific Repeat) 
 Repeat 1 Repeat 2 Repeat 3 Repeat 1 Repeat 2 Repeat 3 
IgG 0.00176776 0.006151 0.002326 0.51766933 1.801312114 0.681018556 
Elf-1 0.00580092 0.008232 0.006201 3.2815131 1.338296 2.666278 
Ets-1 0.0079467 0.028749 0.009138 4.49535812 4.673704 3.929241 
Elk-1 0.00218507 0.017637 0.003 1.23606913 2.867193 1.289918 
Erg-1 0.00481067 0.001664 0.00213 2.72134293 0.27058 0.91574 
 
PC-3 
    Normalized to IgG =1 
  % of Input  
Ct Values 
 Each ETS factor value divided by their IgG 
value (Specific Repeat) 
 Repeat 1 Repeat 2 Repeat 3 Repeat 1 Repeat 2 Repeat 3 
IgG 0.002959 0.011679 0.002208 0.526877 2.079872 0.393251 
Elf-1 0.00391 0.013883 0.005805 1.321646 1.188717 2.628612 
Ets-1 0.003109 0.010036 0.008578 1.050672 0.859298 3.884504 
Elk-1 0.002179 0.006814 0.005149 0.736637 0.583471 2.331594 
Erg-1 0.000815 0.005541 0.002932 0.275611 0.474414 1.327559 
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DU-145 
    Normalized to IgG =1 
  % of Input  
Ct Values 
 Each ETS factor value divided by their IgG 
value (Specific Repeat) 
 Repeat 1 Repeat 2 Repeat 3 Repeat 1 Repeat 2 Repeat 3 
IgG 0.012792 0.005282 0.003049 1.816766 0.750208 0.433026 
Elf-1 0.027784 0.01507 0.003291 2.172081 2.852932 1.07955 
Ets-1 0.022853 0.010897 0.013485 1.786587 2.063086 4.422889 
Elk-1 0.023116 0.009505 0.007778 1.807154 1.799373 2.551158 
Erg-1 0.037161 0.003261 0.01011 2.905107 0.617293 3.31587 
 
 Analysis was performed using the relative quantitative comparative threshold cycle 
(ΔΔCt) method against input chromatin levels and repeated measures ANOVA analysis for 
multiple comparisons against IgG followed by an uncorrected Fisher’s LSD statistical analysis 
(p<0.05 for significance) using Prism 6 software (Graphpad Prism, California, USA) 
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A3- Elf-1 knockdown in 22Rv1 Ct values 
Table A 2 - Ct values for Elf-1 Knockdown in 22Rv1 
 
 
 
 
 
 
CT VALUES
1st REPEAT B-actin Elf-1 Pygopus
Non-targetting C 20.29896 27.774904 31.13721
Non-targetting C 20.61861 27.645544 31.78226
SiRNA Elf-1 20.35332 30.005264 31.89041
SiRNA Elf-1 20.59588 30.205086 31.82758
CT VALUES
2nd REPEAT B-actin Elf-1 Pygopus
Non-targetting C 19.28202 27.196129 30.55829
Non-targetting C 19.47549 27.036165 30.77224
SiRNA Elf-1 20.77568 30.50515 32.77407
SiRNA Elf-1 20.81149 30.746807 32.87446
CT VALUES
3rd REPEAT B-actin Elf-1 Pygopus
Non-targetting C 20.3917 27.105814 31.92888
Non-targetting C 20.6238 26.888554 31.68921
SiRNA Elf-1 20.37768 28.902636 31.62083
SiRNA Elf-1 20.89203 28.994549 32.59383
CT VALUES
3rd REPEAT B-actin Elf-1 Pygopus
Non-targetting C 20.0489 27.563349 31.02946
Non-targetting C 20.0208 27.501993 31.16687
SiRNA Elf-1 18.92608 28.345097 30.9332
SiRNA Elf-1 18.89705 30.896122 29.71433
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A4- Expression of Ets-1 variants in prostate cancer cell lines 
 Expression of Ets-1 in different prostate cancer cell lines and the expression of the three 
main splicing variants that could be identifiable. The ETS-1 gene encodes three different 
variants, full length ETS-1 p51 protein, ETS-1 p42 lacking exon VII, and ETS-1 p27 missing 
exons III-VI (Koizumi et al., 1990; Shaikhibrahim et al., 2011).  In order to assess expression of 
the different Ets-1 variants, immunoblot analysis was performed using the rabbit polyclonal C-
20 anti-ETS-1 antibody directed against the DNA-binding domain in PrEC, 22Rv1, LNCaP, 
MDA PCa 2b, DU-145 and PC-3 cell lines. Results show high expression of the full length 
protein ETS-1 p-51 in normal prostate epithelial cell line PrEC, LNCaP, DU145, MDA PCa 2b, 
PC-3. The variant ETS-1 p42 is highly expressed in PC-3 and ETS-1 p27 variant appears to only 
be expressed in PrEC, DU-145 and MDA PCa 2b. These results provide evidence that ETS-1 
variants protein levels are expressed differently depending on the prostate cell line. 
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Figure A 1 - ETS-1 variants protein expression in prostate cell lines 
Protein expression levels of the main three protein variants of ETS-1 were identified by immunoblot. 
Full length ETS-1 p51 protein appears to be expressed in all of the cell lines including the normal 
prostate epithelium however there is lower expression of it in 22Rv1 cell line. Spliced variant ETS-1 
p42 is highly expressed in PC-3, followed by 22Rv1 compared to PrEC cell line. Lower expression of 
the second spliced variant ETS-1 p-27 is identifiable in PrEC, DU-145 and MDA PCa 2b. 
 
A5- ETS-1 siRNA knockdown was unsuccessful at the protein level  
 ETS-1 knockdown experiments were performed in the 22Rv1 and PC-3 cell line using an 
ON-TARGETplus ETS-1 siRNA (ON-TARGETplus siRNA with target sequences: 5’-
GAUAAAUCCµGUCAGUCUU-3’; 5’-GGACCGµGCµGACCUCAAU-3’; 5’-
GGAAUUACUCACµGAUAAA-3’ and 5’-GCAUAGAG-AGCUACGAUAG-3’, GE Dharmacon 
Healthcare Inc; Colorado, USA) targeting 4 different variants of ETS-1 protein. Unexpectedly, 
Ets-1 protein levels were no different from that of the non-targeting control siRNA sµggesting 
that the knockdown was ineffective. Repeats were performed for each experiment using a range 
of concentration from 5nM to 40nM with the identical negative result. While siRNA transfection 
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protocol was performed identically as previously mentioned in Elf-1 knockdown experiments, a 
literature review confirmed the ON-TARGETplus ETS-1 siRNA has not been validated in 
prostate cell lines. For both cell lines, hPygo2 protein levels were analyzed by immunoblot to 
observe any potential effect induced by the siRNA transfection. Results show no change in 
hPygo2 levels and are not conclusive due to the lack of ETS-1 knockdown confirmation Figure 
A2. An in silico analysis using siRNA-Check tool from National Cancer Institute (In Silico 
Solutions, 2013) was performed obtaining each of the four siRNA sequences provided in the 
ON-targetplus ETS-1 siRNA from Dharmacon resulting in the identification of the target gene 
and mRNA genBank entries that confirmed they correspond to ETS-1 mRNA homologs and 
splice variants. Results also show that siRNA sequences target exons IV and X Figure A3. 
Additional experiments need to be implemented in order to confirm the effectiveness of the ON-
TARGETplus ETS-1 siRNA provided.  
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Figure A 2 - ETS-1 siRNA knockdown in 22Rv1 and PC-3 
A- ETS-1 siRNA knockdown was performed on 22Rv1 cell line but the effectiveness could not be 
evaluated due to the lack of reduction on ETS-1 protein levels, hPygo2 levels did not show any change 
following knockdown. B- ETS-1 siRNA knockdown was performed on PC-3 cell line showing the same 
case, the lack of reduction on ETS-1 protein levels and hPygo2 levels did not show any change in 
protein levels compared to non-targeting control. 
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Figure A3- ETS-1 siRNA target in silico analysis 
In silico analysis using siRNA-Check tool from National Cancer Institute was performed using the 
siRNA sequences provided in the ON-targetplus ETS-1 siRNa. Results confirm siRNA sequences target 
ETS-1 mRNA homologs and the three variants previously mentioned. 
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